<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Oncology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CA56942E-18DE-45C1-8F45-6C572E0F1D0A"><gtr:id>CA56942E-18DE-45C1-8F45-6C572E0F1D0A</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>Barrie</gtr:otherNames><gtr:surname>La Thangue</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0500905"><gtr:id>19803CA7-556A-490C-BC32-3C58E750C90C</gtr:id><gtr:title>The E2F pathway of growth control</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500905</gtr:grantReference><gtr:abstractText>Cancer results from abnormal cell growth and division, and is frequently described as a disease of the cell cycle. The cell cycle refers to the process through which one cell grows and divides which, in normal healthy cells, is a tightly regulated process. The cell cycle is divided into four phases, where a major point of control exists as cells progress from the initial G1 phase into S phase, which is when cells begin to synthesise and copy their DNA in preparation for cell division. In mammalian cells, E2F is a control protein of central importance because it governs whether cells do or do not enter S phase. The activity of E2F is regulated by a number of key proteins that act as a ?braking? system, and includes the retinoblastoma tumour suppressor protein (pRb) which, by forming a protein complex with E2F, blocks E2F activity. Most importantly, in human tumour cells pRb is usually inactive, which means that the normally tightly regulated E2F activity is unleashed, providing a permanent signal that drives cells into unrestrained growth and division. The programme of study described here wants to dissect the role and regulation of different types of E2F activity, and assess the contribution to normal and tumour cell growth. Because of the abnormal control of E2F in cancer, this study is likely to identify new therapeutic opportunities for preventing the growth of tumour cells.</gtr:abstractText><gtr:technicalSummary>The E2F family of heterodimeric transcription factors plays a central role in regulating cellular proliferation by controlling the expression of genes required for cell cycle progression. E2F is regulated in a cell cycle-dependent manner, principally through its temporally regulated association with pocket protein family members, such as the retinoblastoma tumour suppressor protein (pRb), the gene for which is frequently mutated or functionally inactivated in human tumour cells leading to the release of aberrant levels of E2F. Pocket proteins are regulated through phosphorylation by cyclin-dependent kinases, which modulate the interaction between pRb and E2F. In turn E2F transcriptional activity is governed by the physical interaction of co-activator protein complexes with the transcriptional activation domain. As such, E2F is controlled by a pathway that links the machinery of the cell cycle with the transcription apparatus. More recently, the E2F pathway has been shown to be under DNA damage control, which leads to apoptosis. The focus of this programme is to address an interconnected series of questions towards gaining a detailed understanding of the E2F pathway of control. The proposals capitalize on novel insights generated in previous studies on the role of E2F in the DNA damage response together with recent findings on new E2F subunits that exhibit some unusual properties. Given the fundamental role that the pRb/E2F pathway plays in regulating growth, together with its frequent deregulation in human tumour cells, it is likely that the information gained from this study will not only impact on our knowledge of normal growth control, but also provide new insights into cancer cell growth.</gtr:technicalSummary><gtr:fund><gtr:end>2011-05-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1202653</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Structural Genomics Consortium (SGC)</gtr:department><gtr:description>Structural elucidation of epigenetic regulators</gtr:description><gtr:id>8FAB0FC0-3815-483E-B96C-A3D22B336E48</gtr:id><gtr:impact>Publication of the following papers:
Carr SM, Munro S, Zalmas LP, Fedorov O, Johansson C, Krojer T, Sagum CA, Bedford MT, Oppermann U, La Thangue NB. (2014) Lysine methylation-dependent binding of 53BP1 to the pRb tumor suppressor. Proc Natl Acad Sci U S A. Jul 21. pii: 201403737. [Epub ahead of print]

Munro, S., Oppermann, U. and La Thangue, N.B. (2013) Pleiotropic effect of somatic mutations in the E2F subunit DP-1 gene in human cancer. Oncogene, doi: 10.1038/onc.2013.316. Oncogene 33 (27); 3594-603

Carr SM, Munro S, Kessler B, Oppermann U, La Thangue NB (2011) Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein. EMBO Journal 30: 317-327</gtr:impact><gtr:partnerContribution>Structural biology</gtr:partnerContribution><gtr:piContribution>Cancer Biology</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clinical Pathology</gtr:description><gtr:id>43517B6F-5F39-48BB-B2A3-72D031BC55EA</gtr:id><gtr:impact>Publication of the following article:

Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards R. and La Thangue, N. B. (2009) Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15 57-66.</gtr:impact><gtr:partnerContribution>Pathology expertise</gtr:partnerContribution><gtr:piContribution>Cancer Biology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Proteomics</gtr:description><gtr:id>A0F7B3F9-952F-4263-9719-05B14FD638D8</gtr:id><gtr:impact>Publication of the following papers:
Maniam, S., Coutts, A.S., Stratford, M.R., McGouran, J., Kessler, B., and La Thangue, N.B. (2014) p53 regulates oxidative phosphorylation through ATP synthase, Cell Death and Differentiation: in press
Jansson, M., Durant, S.T., Cho, E.C., Sheahan, S., Edelmann, M., Kessler, B., and La Thangue, N.B. (2008). Arginine methylation regulates the p53 response. Nature Cell Biology 10, 1431-1439.</gtr:impact><gtr:partnerContribution>Mass spectrometry</gtr:partnerContribution><gtr:piContribution>Cancer Biology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Journal</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4541D70D-A331-47E7-9384-0525F3D7FE9A</gtr:id><gtr:impact>contribute to journal

distribution to public</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open days</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>872179B7-25C3-4170-8C02-95EDF4253CF4</gtr:id><gtr:impact>Open days, seminars to the lay public, general reviews in lay journals

More awareness</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seminar</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A59F1117-8440-4E0C-8B75-295DF6DA6D25</gtr:id><gtr:impact>Seminar to public

wider understanding</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The E2F pathway of growth control</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BE1F0B67-3686-49AF-A917-1826CB7DB172</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Researchers became specalized in Cancer Research and non-researchers became aware of developments in Cancer Research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1AA22BFF-9475-4554-A150-8134B5656B38</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New antibodies and clones for E2F subunits</gtr:description><gtr:id>978D29E7-FFE9-4430-B1D4-A3FBAEF5E15E</gtr:id><gtr:impact>Wider impact of research into cancer</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Antibodies and clones for E2F subunits</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Celleron Therapeutics</gtr:companyName><gtr:description>Therapeutic Company; http://cellerontherapeutics.com/</gtr:description><gtr:id>D7A34D90-B15A-4A57-AC5A-8FC3B7FD78AE</gtr:id><gtr:impact>Drug discovery</gtr:impact><gtr:url>http://cellerontherapeutics.com/</gtr:url><gtr:yearCompanyFormed>2006</gtr:yearCompanyFormed></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>Profilix</gtr:companyName><gtr:description>Therapeutic; merged with TopoTarget in 2002</gtr:description><gtr:id>EF5A7AAF-578C-4949-AC52-6073E12C7AF9</gtr:id><gtr:impact>Drug development</gtr:impact></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>Oxford Cancer Biomarkers</gtr:companyName><gtr:description>http://oxfordcancerbiomarkers.com/index2.php</gtr:description><gtr:id>76CC19EA-F61B-48F1-AB1F-A5849EB11984</gtr:id><gtr:impact>0</gtr:impact><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/96D288AC-E965-434A-BC1C-2F0FFFC70EB2"><gtr:id>96D288AC-E965-434A-BC1C-2F0FFFC70EB2</gtr:id><gtr:title>TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ade538f7492abc96c06f942de91652f"><gtr:id>4ade538f7492abc96c06f942de91652f</gtr:id><gtr:otherNames>New M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7325BB90-37A7-460E-A8E7-579336BDFD00"><gtr:id>7325BB90-37A7-460E-A8E7-579336BDFD00</gtr:id><gtr:title>To live or let die - complexity within the E2F1 pathway.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e4b1d53b64045b4809079e1aabcead13"><gtr:id>e4b1d53b64045b4809079e1aabcead13</gtr:id><gtr:otherNames>Poppy Roworth A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2372-3556</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A2C71674-4378-4443-AA5E-0A2A67E46852"><gtr:id>A2C71674-4378-4443-AA5E-0A2A67E46852</gtr:id><gtr:title>Strap: a versatile transcription co-factor.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e8d926f151e1a5ca9c91291369227789"><gtr:id>e8d926f151e1a5ca9c91291369227789</gtr:id><gtr:otherNames>Xu D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/64B761E0-95F2-411F-AD1D-C13184A930CB"><gtr:id>64B761E0-95F2-411F-AD1D-C13184A930CB</gtr:id><gtr:title>Structural analysis of human KDM5B guides histone demethylase inhibitor development.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7bee931d752a276728f5b7a8b416a9c9"><gtr:id>7bee931d752a276728f5b7a8b416a9c9</gtr:id><gtr:otherNames>Johansson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/55A387E9-6614-47AB-8AEB-1DF440BB8009"><gtr:id>55A387E9-6614-47AB-8AEB-1DF440BB8009</gtr:id><gtr:title>Lysine methylation-dependent binding of 53BP1 to the pRb tumor suppressor.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8e154330a717af1010273fbe531c4567"><gtr:id>8e154330a717af1010273fbe531c4567</gtr:id><gtr:otherNames>Carr SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AD1C12DD-4171-4F88-AFC3-66DFED8E60B0"><gtr:id>AD1C12DD-4171-4F88-AFC3-66DFED8E60B0</gtr:id><gtr:title>Post-translational control of transcription factors: methylation ranks highly.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8e154330a717af1010273fbe531c4567"><gtr:id>8e154330a717af1010273fbe531c4567</gtr:id><gtr:otherNames>Carr SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E425ED56-09C2-4E1D-8EA7-F89DC6FECD87"><gtr:id>E425ED56-09C2-4E1D-8EA7-F89DC6FECD87</gtr:id><gtr:title>Mdm2 widens its repertoire.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF8424BB-9D23-4685-AE40-B9F48C909430"><gtr:id>BF8424BB-9D23-4685-AE40-B9F48C909430</gtr:id><gtr:title>Selective inhibition of BET bromodomains.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/82d26cad18a3b34bdf077e0d3b841513"><gtr:id>82d26cad18a3b34bdf077e0d3b841513</gtr:id><gtr:otherNames>Filippakopoulos P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E40BC2BB-F82D-4E47-AB29-6A77964A3EB2"><gtr:id>E40BC2BB-F82D-4E47-AB29-6A77964A3EB2</gtr:id><gtr:title>Cofactor Strap regulates oxidative phosphorylation and mitochondrial p53 activity through ATP synthase.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b58dcf49b89d2c6b1a1ed379a31a048b"><gtr:id>b58dcf49b89d2c6b1a1ed379a31a048b</gtr:id><gtr:otherNames>Maniam S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C15BF8AD-3550-40C8-AD1A-32BED2F1F97F"><gtr:id>C15BF8AD-3550-40C8-AD1A-32BED2F1F97F</gtr:id><gtr:title>Clinical Exemplification of HDAC Inhibitors: From Bench to Clinic, and Back Again</gtr:title><gtr:parentPublicationTitle>The Journal of OncoPathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/13c23f382501564b9bd4884d5a95f2ee"><gtr:id>13c23f382501564b9bd4884d5a95f2ee</gtr:id><gtr:otherNames>Olzscha H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5E3DCA01-FEDA-430A-B8D1-44584D23EB4D"><gtr:id>5E3DCA01-FEDA-430A-B8D1-44584D23EB4D</gtr:id><gtr:title>Histone deacetylase inhibitors: gathering pace.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/742a6355de110b9584a2adba20e667a8"><gtr:id>742a6355de110b9584a2adba20e667a8</gtr:id><gtr:otherNames>Carey N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2C546BB7-7F31-4881-A979-031017D3BE0A"><gtr:id>2C546BB7-7F31-4881-A979-031017D3BE0A</gtr:id><gtr:title>eLS</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/13c23f382501564b9bd4884d5a95f2ee"><gtr:id>13c23f382501564b9bd4884d5a95f2ee</gtr:id><gtr:otherNames>Olzscha H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0D221288-6140-4379-9343-C7556D559671"><gtr:id>0D221288-6140-4379-9343-C7556D559671</gtr:id><gtr:title>Actin nucleation by WH2 domains at the autophagosome.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EE8D9523-C4F0-4BDF-A7E6-1AC58740FC81"><gtr:id>EE8D9523-C4F0-4BDF-A7E6-1AC58740FC81</gtr:id><gtr:title>p53 ubiquitination by Mdm2: a never ending tail?</gtr:title><gtr:parentPublicationTitle>DNA repair</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1568-7856</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/38F5AB9B-CC65-4AB8-B64D-A9D692DBFD1F"><gtr:id>38F5AB9B-CC65-4AB8-B64D-A9D692DBFD1F</gtr:id><gtr:title>DNA-damage-responsive acetylation of pRb regulates binding to E2F-1.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e9c0478acc75cd63b43c1995cdddccd"><gtr:id>1e9c0478acc75cd63b43c1995cdddccd</gtr:id><gtr:otherNames>Markham D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/42556632-BB23-4BFA-9433-BAE0E78CF1BA"><gtr:id>42556632-BB23-4BFA-9433-BAE0E78CF1BA</gtr:id><gtr:title>Citrullination-acetylation interplay guides E2F-1 activity during the inflammatory response.</gtr:title><gtr:parentPublicationTitle>Science advances</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/645d826a2aac8cfef39f45eabd8af26e"><gtr:id>645d826a2aac8cfef39f45eabd8af26e</gtr:id><gtr:otherNames>Ghari F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2375-2548</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E3E6B737-31B8-48E1-B264-6529D1415E69"><gtr:id>E3E6B737-31B8-48E1-B264-6529D1415E69</gtr:id><gtr:title>HDAC inhibitor-based therapies and haematological malignancy.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/61162974790942714d2b1debd8527953"><gtr:id>61162974790942714d2b1debd8527953</gtr:id><gtr:otherNames>Stimson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/57B51912-AAE0-411D-865B-1016DFB37B15"><gtr:id>57B51912-AAE0-411D-865B-1016DFB37B15</gtr:id><gtr:title>Lysine methylation regulates the pRb tumour suppressor protein.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e0488141f55304a0a3356e25515e85c3"><gtr:id>e0488141f55304a0a3356e25515e85c3</gtr:id><gtr:otherNames>Munro S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0E864AF1-EFC6-4046-B717-CF3495AAAEBF"><gtr:id>0E864AF1-EFC6-4046-B717-CF3495AAAEBF</gtr:id><gtr:title>Actin nucleation by a transcription co-factor that links cytoskeletal events with the p53 response.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D7EBD5C9-EA5C-4E34-830A-A4A056871F93"><gtr:id>D7EBD5C9-EA5C-4E34-830A-A4A056871F93</gtr:id><gtr:title>Actin nucleators in the nucleus: an emerging theme.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8680c526c850249788ecad73d36a8e3b"><gtr:id>8680c526c850249788ecad73d36a8e3b</gtr:id><gtr:otherNames>Weston L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D75ABF60-B7D6-465E-8F22-64B8786E6D60"><gtr:id>D75ABF60-B7D6-465E-8F22-64B8786E6D60</gtr:id><gtr:title>p53 methylation--the Arg-ument is clear.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5c132eedbf8331b0831d6abf00833683"><gtr:id>5c132eedbf8331b0831d6abf00833683</gtr:id><gtr:otherNames>Durant ST</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/81F41C96-97E6-488D-A472-E095636A5344"><gtr:id>81F41C96-97E6-488D-A472-E095636A5344</gtr:id><gtr:title>A functionally distinct member of the DP family of E2F subunits.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c70ed01dc2e197ce4f897f4f96f5f2dc"><gtr:id>c70ed01dc2e197ce4f897f4f96f5f2dc</gtr:id><gtr:otherNames>Milton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7BCBD60D-A21F-462B-BE67-4996F6BB3ECF"><gtr:id>7BCBD60D-A21F-462B-BE67-4996F6BB3ECF</gtr:id><gtr:title>HDAC inhibitor-based therapies: can we interpret the code?</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ade538f7492abc96c06f942de91652f"><gtr:id>4ade538f7492abc96c06f942de91652f</gtr:id><gtr:otherNames>New M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/95F0D585-97A2-4CDF-A111-0B79122E660F"><gtr:id>95F0D585-97A2-4CDF-A111-0B79122E660F</gtr:id><gtr:title>SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/76532b54344c18c0287d1f9e3a50d7c9"><gtr:id>76532b54344c18c0287d1f9e3a50d7c9</gtr:id><gtr:otherNames>Pfister SX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D27283D2-E48D-4526-B342-3D83F33EBAA4"><gtr:id>D27283D2-E48D-4526-B342-3D83F33EBAA4</gtr:id><gtr:title>Biomarkers for predicting clinical responses to HDAC inhibitors.</gtr:title><gtr:parentPublicationTitle>Cancer letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/61162974790942714d2b1debd8527953"><gtr:id>61162974790942714d2b1debd8527953</gtr:id><gtr:otherNames>Stimson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0304-3835</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/944AF182-61C0-48E5-A048-1129C2642185"><gtr:id>944AF182-61C0-48E5-A048-1129C2642185</gtr:id><gtr:title>ATM and Chk2 kinase target the p53 cofactor Strap.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad778125cc3dc9a3b6408f2e444e67f9"><gtr:id>ad778125cc3dc9a3b6408f2e444e67f9</gtr:id><gtr:otherNames>Adams CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8503D6D4-28EF-4DB7-B407-6BBC35716093"><gtr:id>8503D6D4-28EF-4DB7-B407-6BBC35716093</gtr:id><gtr:title>Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/88d2cb4b08cd1931093e1e6e19a74d41"><gtr:id>88d2cb4b08cd1931093e1e6e19a74d41</gtr:id><gtr:otherNames>Kawalkowska J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/87AD141B-9128-4EE3-B74D-3843AD285B4F"><gtr:id>87AD141B-9128-4EE3-B74D-3843AD285B4F</gtr:id><gtr:title>E2F-1 regulation by an unusual DNA damage-responsive DP partner subunit.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52edaa3d5159d0557a59988fc480ba6f"><gtr:id>52edaa3d5159d0557a59988fc480ba6f</gtr:id><gtr:otherNames>Ingram L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/806B7E42-0BB3-40A9-BA0A-C44BBAA01478"><gtr:id>806B7E42-0BB3-40A9-BA0A-C44BBAA01478</gtr:id><gtr:title>Arginine methylation regulates the p53 response.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ff45642f7a5434862a9ea70b08268fd"><gtr:id>6ff45642f7a5434862a9ea70b08268fd</gtr:id><gtr:otherNames>Jansson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6CDCF41A-2201-476B-A5D2-8BF89A24B3AD"><gtr:id>6CDCF41A-2201-476B-A5D2-8BF89A24B3AD</gtr:id><gtr:title>The p53 response during DNA damage: impact of transcriptional cofactors.</gtr:title><gtr:parentPublicationTitle>Biochemical Society symposium</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0067-8694</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9F0B5D8E-EB70-41E4-AF2A-378A5BC0822A"><gtr:id>9F0B5D8E-EB70-41E4-AF2A-378A5BC0822A</gtr:id><gtr:title>DNA-damage response control of E2F7 and E2F8.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c28a22b36d3a50c513cbeeb2da12fd5"><gtr:id>9c28a22b36d3a50c513cbeeb2da12fd5</gtr:id><gtr:otherNames>Zalmas LP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/821033C2-7005-468D-BBD1-AC697479EB0D"><gtr:id>821033C2-7005-468D-BBD1-AC697479EB0D</gtr:id><gtr:title>A transcription co-factor integrates cell adhesion and motility with the p53 response.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6A256007-AA1C-4689-830A-F06C9052CBE1"><gtr:id>6A256007-AA1C-4689-830A-F06C9052CBE1</gtr:id><gtr:title>14-3-3 proteins integrate E2F activity with the DNA damage response.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e390e2d09ed33768c8a0df64d125ef2a"><gtr:id>e390e2d09ed33768c8a0df64d125ef2a</gtr:id><gtr:otherNames>Milton AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ECD03B52-1B1D-4CF1-B6FD-8C5C6E22D9E8"><gtr:id>ECD03B52-1B1D-4CF1-B6FD-8C5C6E22D9E8</gtr:id><gtr:title>Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1a.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9FA26F00-6CB0-4642-A02F-925363FE81A7"><gtr:id>9FA26F00-6CB0-4642-A02F-925363FE81A7</gtr:id><gtr:title>Mdm2 targets the p53 transcription cofactor JMY for degradation.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B85E8079-BEBF-43CA-8AEE-D2F3E698AEF5"><gtr:id>B85E8079-BEBF-43CA-8AEE-D2F3E698AEF5</gtr:id><gtr:title>E2F-7 couples DNA damage-dependent transcription with the DNA repair process.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c28a22b36d3a50c513cbeeb2da12fd5"><gtr:id>9c28a22b36d3a50c513cbeeb2da12fd5</gtr:id><gtr:otherNames>Zalmas LP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/063D84BE-0808-4BB1-9168-FD31032873C3"><gtr:id>063D84BE-0808-4BB1-9168-FD31032873C3</gtr:id><gtr:title>Atypical E2F activity restrains APC/CCCS52A2 function obligatory for endocycle onset.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/19d155d0032e1658191904ad1cf0d763"><gtr:id>19d155d0032e1658191904ad1cf0d763</gtr:id><gtr:otherNames>Lammens T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9DF3F9FF-6678-49F3-9BE2-9CBCA6F323FC"><gtr:id>9DF3F9FF-6678-49F3-9BE2-9CBCA6F323FC</gtr:id><gtr:title>Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.</gtr:title><gtr:parentPublicationTitle>Nature clinical practice. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cc088ca797e035b292f2f3103320da6b"><gtr:id>cc088ca797e035b292f2f3103320da6b</gtr:id><gtr:otherNames>Khan O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1743-4254</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/968B94FA-6525-41BE-8B49-D711D2AACDC9"><gtr:id>968B94FA-6525-41BE-8B49-D711D2AACDC9</gtr:id><gtr:title>Arginine methylation controls growth regulation by E2F-1.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a8b164c6197f3a8bf63bf411eda6e674"><gtr:id>a8b164c6197f3a8bf63bf411eda6e674</gtr:id><gtr:otherNames>Cho EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D4D1B916-493D-4F5A-8AA5-080593869C65"><gtr:id>D4D1B916-493D-4F5A-8AA5-080593869C65</gtr:id><gtr:title>HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cc088ca797e035b292f2f3103320da6b"><gtr:id>cc088ca797e035b292f2f3103320da6b</gtr:id><gtr:otherNames>Khan O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C2E01038-0CC3-4B84-873F-041860D36363"><gtr:id>C2E01038-0CC3-4B84-873F-041860D36363</gtr:id><gtr:title>The p53 cofactor Strap exhibits an unexpected TPR motif and oligonucleotide-binding (OB)-fold structure.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad778125cc3dc9a3b6408f2e444e67f9"><gtr:id>ad778125cc3dc9a3b6408f2e444e67f9</gtr:id><gtr:otherNames>Adams CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FC76BE0D-1ACB-4C40-91D1-BB49E7CBD062"><gtr:id>FC76BE0D-1ACB-4C40-91D1-BB49E7CBD062</gtr:id><gtr:title>Chromatin control and cancer-drug discovery: realizing the promise.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2221f383d2f23c485cb6fbff36707457"><gtr:id>2221f383d2f23c485cb6fbff36707457</gtr:id><gtr:otherNames>Inche AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0372A10E-0D42-4EDC-A63F-F427CAEBC700"><gtr:id>0372A10E-0D42-4EDC-A63F-F427CAEBC700</gtr:id><gtr:title>Selective inhibition of BET bromodomains.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/82d26cad18a3b34bdf077e0d3b841513"><gtr:id>82d26cad18a3b34bdf077e0d3b841513</gtr:id><gtr:otherNames>Filippakopoulos P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/44B82ACE-FFE7-4BB1-920F-23E9418998DE"><gtr:id>44B82ACE-FFE7-4BB1-920F-23E9418998DE</gtr:id><gtr:title>Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8626d9a61824bfb9a27eeeb65272210e"><gtr:id>8626d9a61824bfb9a27eeeb65272210e</gtr:id><gtr:otherNames>Fotheringham S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F9DE38FF-8320-4C1E-97B3-1681E37DA061"><gtr:id>F9DE38FF-8320-4C1E-97B3-1681E37DA061</gtr:id><gtr:title>CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation.</gtr:title><gtr:parentPublicationTitle>Cell chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/13c23f382501564b9bd4884d5a95f2ee"><gtr:id>13c23f382501564b9bd4884d5a95f2ee</gtr:id><gtr:otherNames>Olzscha H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AF213B4F-0127-4523-9AE0-C021A883BC80"><gtr:id>AF213B4F-0127-4523-9AE0-C021A883BC80</gtr:id><gtr:title>HDAC Inhibitors.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/13c23f382501564b9bd4884d5a95f2ee"><gtr:id>13c23f382501564b9bd4884d5a95f2ee</gtr:id><gtr:otherNames>Olzscha H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7B6FFC45-2D09-4FE2-BA93-8466F957CA09"><gtr:id>7B6FFC45-2D09-4FE2-BA93-8466F957CA09</gtr:id><gtr:title>p53-cofactor JMY is a multifunctional actin nucleation factor.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35fae2d0afc209d7ab79a3f88e8545bc"><gtr:id>35fae2d0afc209d7ab79a3f88e8545bc</gtr:id><gtr:otherNames>Zuchero JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DFC8A8AB-3C2E-4C85-8815-6263FCF83710"><gtr:id>DFC8A8AB-3C2E-4C85-8815-6263FCF83710</gtr:id><gtr:title>Oncology biomarkers in clinical practice - a new horizon</gtr:title><gtr:parentPublicationTitle>Drug Target Review</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c95c284bc6b418511194748af9d10d95"><gtr:id>c95c284bc6b418511194748af9d10d95</gtr:id><gtr:otherNames>Sheikh, S.,</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/765C2793-5E5F-4298-ABBE-D319FBC89477"><gtr:id>765C2793-5E5F-4298-ABBE-D319FBC89477</gtr:id><gtr:title>A transcription cofactor required for the heat-shock response.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e8d926f151e1a5ca9c91291369227789"><gtr:id>e8d926f151e1a5ca9c91291369227789</gtr:id><gtr:otherNames>Xu D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500905</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>